EFS platforms : French blood agency

The EFS pioneers the French production and clinical use of mesenchymal stem cells (MSCs) from bone marrow and adipose tissue (ASC), including the development of security controls and efficacy tests. Four EFS platforms are part of ECELLFRANCE: Toulouse, Créteil, Grenoble and Besançon.

Additionally, the clinical immunological platform in Rennes combines phenotypic and functional tests to qualify the MSC immunological properties and to follow the immune response of MSC treated patients.

• Cell and tissue engineering

• ATMP production units: 

• Production for clinical use, qualification and release of MSC according to the requirements of Good Manufacturing Practices (GMP)
• Technology transfer and development of manufacturing processes
• Scale-up in bioreactors
• Preparation of Investigational Medicinal Product Dossier (IMPD) for authorization of clinical trials

• Immunomonitoring platform: 

• Characterization of immunomodulatory properties of clinical grade MSC towards various immune cells (T and NK cells, monocytes / macrophages, neutrophils) through standardized in vitro tests
• Monitoring of the immune response of patients treated with autologous or allogeneic MSCs (phenotype of immune subpopulations and functional tests before and after administration of MSC

• ATMP production units
• Flow cytometry
• Cell sorting
• Cell culture
• Non clinical studies
• Gene transfert

• MSC/ASC
• ATMP production
• Quality control
• Immunomonitoring